Willkommen, schön sind Sie da!
Logo Ex Libris

Cancer Biomarkers

  • Fester Einband
  • 951 Seiten
"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4... Weiterlesen
CHF 319.00
Auslieferung erfolgt in der Regel innert 2 bis 3 Wochen.

Beschreibung

"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy andother unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc., based molecular markers having high specificity and sensitivity in early diagnosisare emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--

"This book gathers a unique collection of information on cancer biomarkers that will be an invaluable reference for those in the field. It is particularly commendable for its extensive use of tables listing biomarkers, their clinical applications, and the state of clinical validation each has received. By bringing this information together into a single book, the authors provide essential background for the formulation of new diagnostic approaches to individual cancer types not available elsewhere. Weighted numerical score: 81 - 3 stars."
Steven Smith, Ph.D, City of Hope, Duarte, California, USA, from Doody's Book Reviews



Autorentext

Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omicsbased biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 3035 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals.

Dr. Angelo Carpi is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant'Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as Biomedicine & Pharmacotherapy and Frontiers in Bioscience.

Dr. Mukesh Verma is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology.

Mehmet Gunduz, MD, PhD, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international conferences.



Klappentext

This book classifies the available tumor marker according to their principal characteristics and relative methodologies. It presents and discusses the use of the principal tumor markers available for the management of specific cancers (brain, head and neck, oral, gastrointestinal, lung and mesotelioma, urological, gynecological, thyroid, hematological and melanoma). Each chapter represents one type of cancer and is written by physicians or scientists from various countries who blend their clinical experience and scientific expertise in new technologies to provide a definitive account of cancer biomarker discoveries.



Zusammenfassung
nbsp;

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers.

It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information.

Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume

The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers.

Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis

  • Presents noninvasive early molecular markers in urological cancers
  • Describes gynecological and endocrine cancer markers
  • Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers
  • Addresses hematological malignancies 
  • Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin's lymphoma, and multiple myeloma
  • Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma

This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.



Inhalt

Part I General and Technical Aspects

Quality Control and Ethical Issues of Cancer Biomarker Discovery

Anjana Munshi and Vandana Sharma

Imaging Techniques in Cancer Diagnosis

Mohamed Abd El-Salam, Sonia Reda, Salwa Lotfi, Tamar Refaat, and Eman El-Abd

Role of PET in Cancer Diagnosis

Silvia Taralli, Antonella Stefanelli, and Giorgio Treglia

Innovative Tools for Early Detection of Cancer

Ali Tiss, Amal Hasan, Abdelkrim Khadir, Mohammed Dehbi, and Said Dermime

Noninvasive Nanodiagnostics for Cancer

Sandhiya Selvarajan, Melvin George, and Suresh Kumar

Mitochondrial DNA in Early Cancer Diagnosis and Screening

Mukesh Verma, Neelesh Agarwal, and Mudit Verma

Circulating miRNA Biomarkers in Various Solid Cancers

Martina Redova, Hana Mlcochova, and Ondrej Slaby

Stem Cell Biomarkers in Early Diagnosis, Prognosis, and Therapy of Cancer

Dipali Dhawan and Harish Padh

Salivary Biomarkers in Early Diagnosis and Monitoring of Cancer

Saroj K Basak and Eri S Srivatsan

Part II Brain and Head and Neck Cancers

Biomarkers for Brain Gliomas

Yusuf Izci

Noninvasive Biomarkers in Head and Neck Squamous Cell Carcinoma

Anand Kumar, Mumtaz Ahmad Ansari, and Vivek Srivastava

Biological Markers in Oral Squamous Cell Carcinoma

Mario Pérez-Sayáns García, Danielle Resende Camisasca, Abel García García, Simone de Queiroz Chaves Lourenço, and Anastasios Markopoulos

Part III Gastrointestinal Cancers

Biomarkers for Gastric Cancer and the Related Premalignant Conditions

Marcis Leja, Jan Bornschein, Juozas Kupcinskas, and Peter Malfertheiner

Biomarkers in Esophageal Adenocarcinoma

Simon JW Monkhouse, J Muhlschlegel, and H Barr

Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma

Dengfu Yao, Min Yao, Xiaodi Yan, Li Wang, and Zhizhen Dong

Noninvasive Early Markers in Gallbladder Cancer

Mumtaz Ahmad Ansari, Ruhi Dixit, and Vijay Kumar Shukla

Noninvasive Early Markers in Pancreatic Cancer

Aleksandra Nikolic

Part IV Lung Cancer and Mesothelioma

Noninvasive Early Markers in Lung Cancer

Mukesh Verma, Debmalya Barh, and Neha Jain

Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers

in Lung Cancer: Bridging the Gap from Bench to Bedside

Meggie Hakim, Ulrike Tisch, Michael Unger, and Hossam Haick

Part V Urological Cancers

Noninvasive Early Molecular Biomarkers in Kidney Cancer

Brian W Cross, Jonathan Huang, and Viraj A Master

Novel Oncomarkers Used for Earlier Detection of Bladder Carcinoma

Miroslava Bilecová-Rabajdová, Peter Urban, Mária Mareková, and Vincent Nagy

Screening for Prostate Cancer: New Markers and Future Aspects

Nigel P Murray

Part VI Gynecological and Endocrine Cancers

Early Biomarkers in Breast Cancer

Ruchika Kaul-Ghanekar, Snehal Suryavanshi, and Prerna Raina

Noninvasive Biomarkers in Ovarian Cancer

Sharon A O'Toole, Eugen Ancuta, Ream Langhe, Dolores J Cahill, Mairead Murphy,

Cara Martin, Lynda McEvoy, Cathy Spillane, Orla Sheils, Emmanuel Petricoin,

Lance Liotta, and John J O'Leary

Early Markers for Neoplastic Lesions of the Uterine Cervix

Pablo Conesa-Zamora

Biomarkers in Diagnosis of Papillary Thyroid Carcinoma

Marisa Cañadas-Garre, Nuria Muñoz Pérez, Jesús Maria Villar del Moral, José Antonio Ferrón Orihuela, and José Manuel Llamas-Elvira

Biomolecular Markers for Improving Management of Follicular and Medullary

Thyroid Cancer

Umut Mousa, Cuneyd Anil, Serife Mehlika Isldak, Alptekin Gursoy, and Angelo Carpi

Part VII Hematological Cancers

Biomarkers in Myelodysplastic Syndrome

Néstor L López Corrales and Vasco Ariston de Carvalho Azevedo

Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia

Ota Fuchs

Biomarkers in Hodgkin's Lymphoma

Esin Demir, Burak Ylmaz, Mehmet Gunduz, and Esra Gunduz

Multiple Myeloma and Evolution of Novel Biomarkers and Therapies

Michael Byrne, Joseph Katz, and Jan S Moreb

Part VIII Melanoma

Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma

Eijun Itakura and Alistair J Cochran

Index

Produktinformationen

Titel: Cancer Biomarkers
Untertitel: Minimal and Noninvasive Early Diagnosis and Prognosis
Editor:
EAN: 9781466584280
ISBN: 978-1-4665-8428-0
Format: Fester Einband
Herausgeber: Taylor and Francis
Genre: Medizin
Anzahl Seiten: 951
Gewicht: 1905g
Größe: H254mm x B178mm
Jahr: 2014
Zuletzt angesehen
Verlauf löschen